AL-09. The experience with asciminib as a bridge- therapy before allogeneic bone marrow transplantation

[摘要] Asciminib is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that has shown potential efficacy and a good safety profile according to the results of a phase I and III studies in patients with Ph-positive leukemia failing prior TKIs. In Russia, asciminib is available under the Managed Access Program (MAP) approved by Novartis. While pre-transplant use of 2nd generation TKIs (nilotinib/ dasatinib) does not change the adverse events rate in allogeneic hemopoietic stem cell transplantation (allo-HSCT) recipients (Niederwieser C., 2021, Masouridi-Levrat S., 2021), there is yet no data available for patients receiving asciminib. This study was aimed to evaluate the safety and effectiveness of pre- and post-transplant aciminib in allo-HSCT candidates.

[学科分类] 肿瘤学

[关键词] Chronic myeloid leukemia;allo-HSCT;tyrosine kinase inhibitors;asciminib.